DaVita Names New Leaders to Accelerate Care Transformation

DaVita (NYSE: DVA) named Stephanie Hendrickson as Chief People Officer and Steve Phillips as Chief Strategy Officer, effective Dec. 11, 2025.

Rhea-AI Summary

DaVita (NYSE: DVA) named Stephanie Hendrickson as Chief People Officer and Steve Phillips as Chief Strategy Officer, effective Dec. 11, 2025. Both executives bring more than a decade of experience at DaVita and will lead people, strategy, and innovation efforts—Phillips will oversee DaVita Venture Group and corporate strategy. The appointments emphasize a people-first approach and a focus on technology-driven care transformation.

As of Sept. 30, 2025, DaVita served approximately 293,200 patients at 3,247 outpatient centers worldwide, underscoring the scale behind the leadership shift.

Positive

• Appointments effective Dec. 11, 2025
• Both executives have >10 years at DaVita
• Phillips to oversee DaVita Venture Group and corporate strategy
• Scale: ~293,200 patients as of Sept. 30, 2025

Negative

• None.

Argus Dec 11 session

+1.39% close to close Open Argus

Details

News Market Reaction – DVA

On Dec 11, the day this news came out, DVA closed 1.39% above the previous close.

Data tracked by StockTitan Argus for the Dec 11 session.

Market Context

This announcement highlights DaVita’s focus on leadership depth with internal promotions to Chief Pe...

Analysis

This announcement highlights DaVita’s focus on leadership depth with internal promotions to Chief People Officer and Chief Strategy Officer, both tied to its kidney-care growth strategy. In recent months, the company has reported detailed Q3 2025 results, secured new $2 billion term loan A and $1.5 billion revolving facilities, and advanced clinical initiatives. Shares trade below the 200-day MA, and recent insider context reflects Net Selling, so investors may watch how these leaders influence execution and future operating trends.

Key Figures

Q3 2025 revenue: $3.420B Q3 operating income: $506M Q3 adjusted EPS: $2.51 +5 more

Q3 2025 revenue

$3.420B

Consolidated revenue for quarter ended September 30, 2025

Q3 operating income

$506M

Operating income for quarter ended September 30, 2025

Q3 adjusted EPS

$2.51

Adjusted diluted EPS for quarter ended September 30, 2025

Q3 operating cash flow

$842M

Operating cash flow in Q3 2025

Q3 free cash flow

$604M

Free cash flow in Q3 2025

Term loan A facility

$2 billion

New five-year secured term loan A under Eighth Amendment

Revolving credit facility

$1.5 billion

New five-year secured revolving credit facility

Patients served

293,200 patients

As of September 30, 2025 across 3,247 outpatient dialysis centers

Historical Context

5 past events · Latest: Nov 14

5 events

1. Nov 14

   Conference appearance

   24h Move

   -1.2%

   CFO participation in Wolfe Research healthcare conference fireside chat.

2. Nov 04

   Research presentations

   24h Move

   +0.8%

   Six new kidney-care studies showcased at ASN Kidney Week 2025.

3. Oct 29

   Earnings results

   24h Move

   -6.2%

   Q3 2025 results, refinancing, buybacks, and updated 2025 guidance.

4. Oct 20

   Clinical initiatives

   24h Move

   +1.7%

   Launch of MODEL and MEMOIRS studies on middle-molecule clearance.

5. Oct 13

   Earnings call notice

   24h Move

   -0.1%

   Scheduling of Q3 2025 earnings release and investor call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

stock appreciation rights, term loan, revolving credit facility, benchmark rates, +4 more

8 terms

stock appreciation rights financial

"the officer exercised stock appreciation rights covering 5,875 shares"

Stock appreciation rights (SARs) are a form of employee compensation that give the holder the right to receive the increase in a company's stock price over a set baseline, paid in cash or shares, without having to buy the stock. For investors, SARs matter because they can create future cash outflows or share dilution and signal how a company rewards and motivates executives — similar to giving a bonus tied directly to how well the company’s stock performs.

term loan financial

"a new five-year secured term loan A facility of up to"

A term loan is a type of loan that is borrowed for a set period of time, with a fixed schedule for repaying the money, usually in regular payments. It matters to investors because it represents a company's borrowing costs and financial stability; reliable repayment of these loans can indicate strong financial health, while difficulties may signal potential risks.

revolving credit facility financial

"a new five-year secured revolving credit facility of up to"

A revolving credit facility is a type of loan that a business can borrow from whenever it needs money, up to a set limit. It’s like having a credit card for companies—allowing them to borrow, pay back, and borrow again as needed, providing flexibility for managing cash flow or funding short-term expenses.

benchmark rates financial

"with interest based on benchmark rates such as Term SOFR, EURIBOR"

Benchmark rates are widely used reference interest rates set by central banks or established markets that act like a financial yardstick for borrowing and lending costs. Investors watch them because changes shift loan interest, bond yields and the value of stocks and currencies, affecting corporate profits and investment returns much like a change in the baseline temperature alters energy bills and comfort levels.

Term SOFR financial

"based on benchmark rates such as Term SOFR, EURIBOR, or Daily Simple SONIA"

Term SOFR is a benchmark interest rate that reflects the cost of borrowing money over a specific period, based on actual transactions in the financial markets. It is used by lenders and borrowers to set the interest rates on loans and financial contracts, helping to ensure rates are fair and transparent. For investors, understanding term SOFR helps gauge borrowing costs and the overall direction of interest rates in the economy.

EURIBOR financial

"benchmark rates such as Term SOFR, EURIBOR, or Daily Simple SONIA"

Euribor is the benchmark interest rate at which banks in the eurozone lend short-term money to one another and is published for several maturities (overnight to one year). Investors watch it because it forms the baseline for many loans, mortgages, bonds and derivatives—like the temperature reading that helps predict how hot borrowing costs and returns will be across the market.

Daily Simple SONIA financial

"Term SOFR, EURIBOR, or Daily Simple SONIA plus an Applicable Margin"

Daily simple SONIA is a widely used benchmark interest rate that reflects the actual overnight cost of borrowing British pounds, expressed as a straightforward daily rate without compounding. Investors use it to calculate interest payments, price loans, bonds and derivatives in a way similar to using a daily electricity meter reading to set your bill; small day-to-day changes can alter cash flows, valuations and hedging costs for financial contracts tied to it.

Applicable Margin financial

"Daily Simple SONIA plus an Applicable Margin. The initial margin is"

Applicable margin is the extra percentage added to a base interest rate to calculate the actual interest a borrower pays on a floating-rate loan or credit line. Investors care because it directly affects a company’s borrowing cost—higher margins raise interest expense and reduce profit and cash flow, while lower margins make financing cheaper; think of it as a variable surcharge on a sale price that reflects the lender’s view of risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Appointments of Chief People Officer and Chief Strategy Officer underscore commitment to innovation and people-first approach

DENVER, Dec. 11, 2025 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced two key additions to its executive leadership team: Stephanie Hendrickson has been named Chief People Officer (CPO) and Steve Phillips will serve as Chief Strategy Officer (CSO), effective immediately. Both leaders bring more than a decade of proven success at DaVita and deep expertise that will help shape the company's next chapter of growth and innovation.

"At DaVita, people are at the center of everything we do and the foundation for unrivaled care delivery that positively impacts our patients' lives," said Javier Rodriguez, CEO of DaVita. "Stephanie brings a remarkable ability to connect strategy with culture—introducing fresh ideas and a deep understanding of what makes DaVita unique. Her leadership will help us foster purpose, connection, and growth for our teammates. At the same time, Steve's vision and success in launching DaVita Venture Group have accelerated growth and forged valuable partnerships. Together, their strategic leadership will be instrumental in driving our next phase of innovation and leadership in kidney care."

Hendrickson, who joined DaVita in 2013, has built a reputation for building and growing strong teams across the healthcare provider, medical device, and pharmaceutical sectors. She earned her undergraduate degree from California Polytechnic State University, San Luis Obispo and an MBA from the Paul Merage School of Business at the University of California, Irvine.

"Developing teammates across DaVita has been a highlight of my career," said Hendrickson. "As CPO, I look forward to building on this momentum and leading our people team to champion our mission of being an employer of choice, fostering an environment where our people thrive."

As CSO, Phillips will expand his leadership role to oversee both DaVita Venture Group (DVG) and the corporate strategy function. During his tenure, he has led strategic initiatives and investments that support patients across all stages of kidney health. Phillips has a background in healthcare strategy and experience that spans services, pharmaceuticals and medical devices. He holds a bachelor's degree from Lafayette College and an MBA from the University of Virginia's Darden School of Business.

Rodriguez added, "Steve's leadership reflects what's possible when we challenge the status quo in healthcare. His ability to stretch beyond traditional models and forge bold collaborations positions DaVita to lead in delivering innovative, patient-centered solutions."

"We're at an exciting inflection point in healthcare, where new technologies are rapidly transforming care and improving outcomes," said Phillips. "I'm honored to help shape meaningful transformation in kidney care and chronic disease management."

These appointments underscore DaVita's commitment to bold, visionary leadership in healthcare. As care continues to evolve—driven by advancing technologies and changing patient needs—our leaders are focused on shaping solutions that improve outcomes, strengthen communities, and set new standards for care. Together, they will help drive innovation and foster a culture where both patients and teammates can thrive.

About DaVita Inc.
DaVita (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for 25 years. DaVita cares for patients at every stage and setting along their kidney health journey—from slowing the progression of kidney disease to helping to support transplantation, from acute hospital care to dialysis at home. As of September 30, 2025, DaVita served approximately 293,200 patients at 3,247 outpatient dialysis centers, of which 2,662 centers were located in the United States and 585 centers were located in 14 other countries worldwide. DaVita has reduced hospitalizations, improved mortality, helped improve health access and worked collaboratively to propel the kidney care community to adopt a higher quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.

Media Contact:
DaVita Newsroom
newsroom@davita.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/davita-names-new-leaders-to-accelerate-care-transformation-302638579.html

SOURCE DaVita

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who were named to DaVita executive roles on Dec. 11, 2025 (DVA)?

Stephanie Hendrickson was named Chief People Officer and Steve Phillips was named Chief Strategy Officer, effective Dec. 11, 2025.

What responsibilities will Steve Phillips have as DaVita CSO (DVA)?

Phillips will lead corporate strategy and oversee DaVita Venture Group, expanding strategic investments and partnerships.

What is Stephanie Hendrickson’s background as DaVita CPO (DVA)?

Hendrickson joined DaVita in 2013 and has experience across healthcare providers, medical devices, and pharmaceuticals with an MBA from UC Irvine.

How large is DaVita’s patient and center footprint cited in the announcement (DVA)?

As of Sept. 30, 2025, DaVita served ~293,200 patients at 3,247 outpatient dialysis centers worldwide.

How do these leadership changes affect DaVita’s strategic focus (DVA)?

The company says the hires reinforce a people-first approach and aim to accelerate care transformation through innovation and partnerships.